Candel Therapeutics Inc

0.00 (+0.14%)
Earnings Announcements

Candel Therapeutics Inc Reports Q2 Net Loss Per Share Of $0.14

Published: 08/05/2022 12:23 GMT
Candel Therapeutics Inc (CADL) - Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights.
Candel Therapeutics Inc - Cash and Cash Equivalents As of June 30, 2022 Were $86.8 Million Compared to $82.6 Million As of December 31, 2021.
Candel Therapeutics Inc - Expects That Its Existing Cash and Cash Equivalents Will Be Sufficient to Fund Its Operations Into Q1 of 2024.
Candel Therapeutics Inc - Qtrly Net Loss per Share Attributable to Common Stockholders, Basic and Diluted $0.14.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.43

Next Quarter Revenue Guidance is expected to be $0.02 Million
Next Quarter EPS Guidance is expected to be -$0.44

More details on our Analysts Page.